Pfizer Oncology together™

Patient Support Program & Patient Assistance Enrollment Form

When applicable, check the box(es) be	Orals			
enroll in the following services provide	☐ AROMASIN® (exemestane)			
☐ Benefits Verification	Co-Pay Savings Program for Injectables	☐ BOSULIF [®] (bosutinib)		
☐ Pfizer Patient Assistance Program	☐ Care Champion Program	☐ BRAFTOVI® (encorafenib)		
Overview		☐ DAURISMO™ (glasdegib sodium)		
Pf-rev Oncology Together is a personalize	d patient support program that offers resources	☐ EMCYT® (estramustine phosphate sodium		
for patients prescribed Pfizer Oncology m	☐ IBRANCE® (palbociclib)			
support, as well as help identifying finance	☐ INLYTA® (axitinib)			
prescribed Pfizer Oncology medicines. Pfizer is committed to working at every le	☐ LORBRENA® (Iorlatinib)			
medicines a reality across the communit	☐ MEKTOVI® (binimetinib)			
	loes not include all of the indications of the see Section 19 to confirm and acknowledge	\square SUTENT $^{\circ}$ (sunitinib malate)		
program limitations.	☐ TALZENNA® (talazoparib)			
For details about how we collect and us	☐ VIZIMPRO® (dacomitinib)			
applicable U.S. state privacy rights and visit www.pfizer.com/privacy .	☐ XALKORI® (crizotinib)			
Pfizer Oncology Together Pa	Injectables			
By enrolling in Pfizer Oncology Together,	natients will receive various support and	☐ BESPONSA® (inotuzumab ozogamicin)		
information to help access Pfizer medicir	☐ CAMPTOSAR® (irinotecan hydrochloride)			
depending on the program (collectively,	···	☐ ELLENCE® (epirubicin hydrochloride)		
	ation and reimbursement support, including: surer's prior authorization requirements	\square IDAMYCIN $^{\circ}$ (idarubicin hydrochloride)		
 Assisting with identification of the in 	•	☐ MYLOTARG™ (gemtuzumab ozogamicin)		
denied claim	☐ TORISEL® (temsirolimus)			
 Communicating with Healthcare Provice Support Activities 	ers (HCPs) about a Pfizer medicine and Patient			
 Sending a device and starter kit (where 	appropriate)	Injectable – Biosimilars		
 Provision of financial assistance resource 	□ NIVESTYM® (filgrastim-aafi)			
 Determining eligibility for and helping programs (including the Pfizer Patient A 	☐ NYVEPRIA™ (pegfilgrastim-apgf)			
 One-on-one assistance to help address 	□ RETACRIT® (epoetin alfa-epbx)			
 Provision of disease management and o 	□ RUXIENCE™ (rituximab-pvvr)			
about Pfizer's products, services, and pro the patient's experience with Pfizer prod	☐ TRAZIMERA™ (trastuzumab-qyyp)			
		☐ ZIRABEV™ (bevacizumab-bvzr)		
Patients Eligible for the Pfize	r Patient Assistance Program			

To qualify for free medicine, the patient must meet certain financial requirements, as well as meet the criteria below:

- Have a valid prescription for the Pfizer medicine for which they are seeking assistance
- Be 18 years of age or older
- Reside in the U.S. or a U.S. territory
- Be treated by a healthcare provider licensed in the U.S. or a U.S. territory
- Meet one of the following:
 - Have no insurance coverage or not enough coverage to pay for your Pfizer medicine listed above
 - Have been denied coverage by your insurer for the Pfizer medicine listed above (after an unsuccessful appeal to your insurer)
- Meet certain income limits (income limit is 500% of the federal poverty level) Before enrolling in the Pfizer Patient Assistance Program, patients should be sure to fully use all co-pay assistance options available to them.

Your Color Coding Guide

Color coding indicates which sections of the form should be filled out by the

Patient or the HCP

*The Pfizer Patient Assistance Program is a joint program of Pfizer Inc. and the Pfizer Patient Assistance Foundation™. Free medicines from Pfizer are provided through the Pfizer Patient Assistance Foundation™. The Pfizer Patient Assistance Foundation™ is a separate legal entity from Pfizer Inc. with distinct legal restrictions.

Pfizer Oncology together™

TO BE COMPLETED BY PATIENT

Be sure your HCP faxes the **completed** form to 1-877-736-6506 or mail to: Pfizer Oncology Together, PO Box 220366, Charlotte, NC 28222-0366. For questions, please call 1-877-744-5675, Monday–Friday, 8 AM–8 PM ET.

For details about how we collect and use personal information, including applicable U.S. state privacy rights and notices for California residents, please visit www.pfizer.com/privacy.

Enrollment Checklist for Patients								
Pages 2 and 3 should be completed by the patient of	or their caregiver.	Whe	n completing th	ese pages, keep the following	points in mind:			
	Review Section	n 5 ar	nd check the box	if you would Very Read all	Patient Authorizations,			
medical and pharmacy insurance cards	•		Care Champion p		ions, and Disclosures,			
Include proof of income, such as page 1 of your tax return, if you are seeking	Check the appr		te boxes in Sect for text messag		n in Section 5 to provide			
financial assistance through the Pfizer				c alcito iloili				
financial assistance through the Pfizer the Pfizer Patient Assistance Program and/or from Patient Assistance Program (PAP)† Pfizer Oncology Together Care Champion								
1. Patient Information					*Required fields			
Name (First/MI/Last)*		Pati	ent DOB (mm/dd/y	уууу)*	Sex*□Male □Female			
Street Address*								
City*		Stat	e*	ZIP	Code*			
Phone* ☐ Home ☐ Mob	ile 🗆 Work	Emo	ıil Address					
Best Time to Contact Morning Afternoon Eve	ening	Pref	erred Language (if	not English)				
Caregiver Name		Care	egiver Phone		☐ Home ☐ Mobile ☐ Work			
Patient I give permission to Pfizer Oncolog				3 1	ncology Together to communicate			
Authorizations: messages for me about patient ser	rvices and enrollmen	nt stati	JS.	directly with my caregiver or	ı my behalf.			
2. Patient Insurance Information								
Check insurance type: ☐ Commercial ☐ Medicare ☐ I	Medicαid L Other	r			_ □ None (skip to Section 3)			
Primary Insurance*				Insurer's Phone*				
Policy/Medicare Beneficiary ID #*			GRP ID #*					
Policyholder same as patient? Yes No Relationship to F								
Policyholder Name*			Policyholder DOB (mm/dd/yyyy)					
Secondary Insurance*				Insurer's Phone*				
Policy/Medicare Beneficiary ID #*		GRP ID #*						
Policyholder same as patient? ☐ Yes ☐ No	Relationship to Po							
Policyholder Name* Policyholder DOB (mm/dd/yyyy)								
Is the Pfizer medication covered by either medical or prescription insurance? Yes No I don't know If yes, what is the co-pay amount? It don't know Prescription Insurance Name*								
Prescription Insurance Name*								
Prescription Group ID #* Prescription BIN # Prescription PCN #*								
Are you enrolled in a Medicare Part D Prescription Drug Plan? Yes \(\subseteq \text{No}\) (If Yes, please complete the information below. If No, skip to Section 3)								
Provide your Medicare ID Number (HICN) or Medicare Beneficiary Number (MBI) Medicare Part D Plan Name								
Medicare Part D Plan Name Medicare Part D Plan Address								
Note: Include copies of the front and back of your medical	and pharmacy insu	rance	cards with your on	rollment form				
3. Patient Financial Information	and priarmacy made	Turice	cards with your en	TOTAL TOTAL				
This information is required to search for alternate funding support and verify eligibility for the Pfizer Patient Assistance Program, as appropriate.								
Do not provide financial information if you are only applying for the Pfizer Oncology Together Co-Pay Savings Program for Injectables. Total Number of People Within Household (including applicant) Total Annual Household Income \$								
Please submit documentation to support the financial information you've listed. Attached is:								
Most recent federal tax return (Page 1 of IRS 1040 form) □ W-2 form □ Other								
4. Pfizer Oncology Together Co-Pay Savings Program for Injectables								
Check the appropriate box below if you are requesting enrollment in the Pfizer Oncology Together Co-Pay Savings Program for Injectables for the following product: NIVESTYM®, NYVEPRIA™, RUXIENCE™, TRAZIMERA™, and ZIRABEV™.								
Yes No I authorize the Pfizer Oncology Together Co-Pay Savings Program for Injectables ("Program") to provide payment directly to my healthcare provider, and not to								
me, for my out-of-pocket drug costs for my Pfizer Oncology medicine. I authorize my healthcare provider to contact the Program on my behalf to initiate payment for services after they have been rendered. I understand that I will be responsible for any out-of-pocket expenses for my Pfizer Oncology medicine if (1) my healthcare provider does not								
request payment within 120 days of the issue date on my Explanation of Benefits (EOB), or (2) if I am deemed ineligible for reimbursement from the Program.								
☐ Yes ☐ No I attest that I am not enrolled in a state or federally funded insurance program, including but not limited to, Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as "La Reforma de Salud"). I attest that I am not								
over 65 years of age and retired. I attest that I do not receive Social Security Disability (SSDI) or any other Social Security Administration (SSA) benefit. I attest that I do not								
have End Stage Renal Disease (ESRD). I further attest that I am not active duty military nor are any of my immediate family members.								
Terms and Conditions apply. For full Terms and Conditions for injectable products, please see PfizerOncologyTogether.com/injectables-terms and select the product								

TO BE COMPLETED BY PATIENT

$\textbf{Pfizer Oncology} \ together^{^{\text{\tiny{T}}}}$

Be sure your HCP faxes the **completed** form to 1-877-736-6506 or mail to: Pfizer Oncology Together, PO Box 220366, Charlotte, NC 28222-0366. For questions, please call 1-877-744-5675, Monday—Friday, 8 AM—8 PM ET.

For details about how we collect and use personal information, including applicable U.S. state privacy rights and notices for California residents, please visit www.pfizer.com/privacy.

rights and notices for California residents, please visit www.pfizer.com/privacy .								
5. Patient Authorizations, Attestations, and Disclosures		*Required fields						
ersonalized Patient Support Opt-in (Optional) ersonalized patient support is offered through Pfizer Oncology Together via Care Champion. You can speak with Care Champion for resources that may help with your daily fe. Your Care Champion may provide information about your condition, Pfizer Oncology medicine, or topics such as nutrition, as well as a co-pay card offer for eligible patients. are Champion can also connect you to independent organizations that provide services such as transportation and lodging for your treatment-related appointments. These fferings may vary based on your prescribed medicine. To opt in to this program, please check the box below.								
By checking this box, I request Care Champion support and agree to communications from Pfizer Oncology Together, Pfizer, and/or parties acting on their behalf. These communications may include calls to my phone number made with an autodialer about resources and other support such as those described above. I understand that my consent is not required or a condition of purchasing any Pfizer goods or services. I understand that I can opt-out of these communications at any time by contacting Pfizer Oncology Together at 1-877-744-5675.								
You can receive communications from the Care Champion program via text message. By checking this box, I consent to receive autodialed marketing and other texts from Pfizer and its service providers regarding the Pfizer Oncology Together Care Champion program at my mobile phone number,								
Pfizer Patient Assistance Program [†] Certification, Attestation, and Privacy Disclosures	•							
By signing the form, I certify that I cannot afford my medication, and I affirm that my a the best of my knowledge. I will promptly contact the Pfizer Patient Assistance Program i medicine or any cost from it counted in my Medicare Part D out-of-pocket expenses for pr my prescription insurance provider or payor, including Medicare Part D plans. I will notify Assistance Program. I have a signed copy of a current and completed HIPAA Authorization me with Pfizer's assistance programs, Pfizer Inc., and the Pfizer Patient Assistance Foundat The information you provide will be used by Pfizer, Pfizer Oncology Together, the Pfizer P eligibility, to manage and improve Pfizer's assistance programs, to communicate with you	if my financial status or insurance coverage changes. I escription drugs. I will not seek reimbursement or credit my insurance provider of the receipt of any medicines t Form on record with my HCP so that my HCP may share I ion, Inc. 'atient Assistance Foundation™, and parties acting on t about your experience with Pfizer's assistance programs	will not seek to have this for the medicine(s) from hrough the Pfizer Patient nealth information about heir behalf to determine s, to help you understand						
your insurance coverage and help you access certain Pfizer medicines through your insurance, and/or to send you materials and other helpful information and updates relating to Pfizer programs. I understand that: completing this enrollment form does not guarantee that I will qualify for Pfizer's assistance programs. Pfizer may contact my insurer, to help me understand my insurance coverage for certain products and may provide me support to obtain coverage through my insurer, including prior authorization and appeals support (if necessary and available). Pfizer may verify the accuracy of the information I have provided and may ask for more financial and insurance information. Any medicines supplied by Pfizer's assistance programs shall not be sold, traded, bartered, or transferred. Pfizer reserves the right to change or cancel Pfizer's assistance programs, or terminate my enrollment, at any time. The support provided through this program is not contingent on any future purchase. If I am enrolled in a Medicare Part D Plan and am eligible for the Pfizer Patient Assistance Program. Pfizer will notify my Part D Plan of my enrollment in the Pfizer Patient Assistance Program. Text me about my refills! By checking this box, I consent to receive refill reminders and shipping texts if I am accepted into the Pfizer Patient Assistance Program. I will receive a welcome text asking me to reply CONFIRM to opt in. Messages and data rates may apply. Number of messages varies based on program use, but is up to 5 texts per month. Reply STOP to cancel. Privacy policy and full Terms available here: www.pfizer.com/privacy . Please enter the number you would like to enroll for texting								
Patient Consent to Receive Communications By signing this form, I agree to receive communications from Pfizer, Pfizer Oncology Toget benefits verification, prior authorization/appeals assistance, and financial assistance resour non-marketing purposes. I agree to be contacted by Pfizer, Pfizer Oncology Together, or par voice at the telephone number(s) provided. If I have a caregiver, he or she has also agree parties acting on their behalf for the purposes described above, and I hereby give my perm contact my caregiver for such purposes. I understand that I (and, if applicable, my caregiver Together at 1-877-744-5675, Monday—Friday, 8 AM—8 PM ET.	rces and information, such as co-pay support or free drug ties working on their behalf for these purposes using an o ed to receive such communications from Pfizer, Pfizer Or ission for Pfizer, Pfizer Oncology Together, and/or parties	g programs, and for other autodialer or prerecorded acology Together, and/or acting on their behalf to						
Patient Signature* (Patient or personal representative of patient)	If personal representative, indicate relationship.	Date*						
Patient Email Address (Provide if signing electronically):								
Patient Authorization for Electronic Income Verification (Optional – Only if applying f I, the applicant name below, understand that I am providing "written instructions" to and parties acting on their behalf under the Fair Credit Reporting Act authorizing the F information from Experian™ Income View™. I authorize Pfizer to obtain such informations Assistance Program. I also agree to provide additional financial documentation in a time terms in this notice by signing below in order to proceed in the Pfizer Patient Assistance I understand that I am entitled to a copy of this Authorization upon request. This Authori (unless a shorter period is prescribed by law). I understand that I may cancel this Authorizat Together, PO Box 220366, Charlotte, NC 28222-0366, but that this cancellation will not Patient Authorization for Financial Screening: My signature certifies that I have read and	o Pfizer, Pfizer Oncology Together, the Pfizer Patient A Pfizer Oncology Together to obtain information from nolely for the purpose of determining financial qualificatiely manner, if so requested. I understand that I must a Program financial screening process. Ization shall be valid for two (2) years from the date of too ion at any time by mailing a letter requesting such cance apply to any information already used or disclosed thro	ny credit profile or other ions for the Pfizer Patient ffirmatively agree to the he signature of this form Illation to Pfizer Oncology ough this Authorization.						
Patient Signature* (Patient or personal representative of patient)	If personal representative, indicate relationship.	Date*						
Patient Email Address (Provide if signing electronically):								

TO BE COMPLETED BY HCP

Pfizer Oncology together™

HCPs fax the **completed** form to 1-877-736-6506 or mail to: Pfizer Oncology Together, PO Box 220366, Charlotte, NC 28222-0366. For questions, please call 1-877-744-5675, Monday–Friday, 8 AM–8 PM ET.

For details about how we collect and use personal information, including applicable U.S. state privacy rights and notices for California residents, please visit www.pfizer.com/privacy.

Enrollment Checklist for HCP

Fill out every section of this page for all patient enrollment requests. Read the **Privacy and Consent** statements in Sections 9 and 10 and sign below. On the following pages:

- Diagnosis: Specify diagnosis in Section 12 for Oral and/or Injectable medications, and in Section 19 for Injectable Biosimilar Medications. For RUXIENCE™ or ZIRABEV™: Check the box and sign to acknowledge program limitations.
- Directions/Dosing Instructions: Complete Section 13 for Orals and/or Section 17 for Injectables
- Sign the Prescription: Sign Section 14 for Orals
- Pfizer Patient Assistance Program: For patients requesting enrollment for Orals and/or Injectables, Section 8 is required. For patients requesting enrollment for Injectable Biosimilars, Sections 8, 22, and 23 are required

<u>Please Note:</u> When e-prescribing, if you cannot find AmeriPharm (NPI number–1073692745; NCPDP number–4351968), you can also search for MedVantx under retail pharmacies (NPI number–1235371535; NCPDP number–4354180). The prescription will be sent to the same place.

6. Patient Information							*Required fields
Patient Name (First/MI/Last)* Patient DOB (mm/dd/yyyy)*							
Is your patient's Pfizer medication covered by either medical or prescription insurance? ☐ Yes ☐ No ☐ I don't know \$ ☐ I don't know					nt?		
7. HCP/Site of Care Information							
HCP Name (First/MI/Last)*						Professional Desig	gnation
Practice/Institution Name*		Address	*				
City*				State*		ZIP Code*	
NPI*	Group Tax ID*		State Licen	se*		DEA	
Fax*	Email						
Site of Care Location*: Provider's office	e Hospital outpatient 🛘	Hospital inp	oatient \square Ot	her \square N/A			
Contact Name*			Contact Ph	one*			
8. Shipping Information for Pfizer Pati	ent Assistance Program (PAP) I	Patients ((Required if re	equesting assistan	ce through Pfiz	er Patient Assistance P	rogram.†)
Patient Name*							
Ship To*: HCP/Site of Care Address (Section 7) Patient Address (Section 1) Administering Provider Address (Section 20) Other Address (Fill out the required information below.)							
Address*							
City* State* ZIP Code*							
Office Name* Contact Phone*							
9. Healthcare Provider Consent							
I understand that completing this enrollment form does not guarantee that assistance will be provided to my patient. I will receive and secure my patient's medication at my office until it's dispensed to my patient, when applicable. I will comply with and abide by my State Practitioner Dispensing Laws for authorized Prescribers, when applicable. Any medications supplied by Pfizer as a result of this enrollment form are for the use of the patient named on this form only and shall not be sold, traded, bartered, transferred, returned for credit, or submitted to any third party (such as Medicare, Medicaid, or other benefit provider) for reimbursement. The medicine will be provided only to this eligible and enrolled patient at no charge of any kind. The information provided on this enrollment form is subject to random audits and verification. Pfizer may change or cancel this program at any time; Pfizer also reserves the right to terminate my patient's enrollment at any time.							
10. Healthcare Provider HIPAA and Telephone Consumer Protection Act (TCPA) Attestation							
By my signature, I certify that I have obtained any and all authorizations and consents from the patient or the patient's authorized personal representative necessary under HIPAA and state law to release protected health information, including that contained on this form, to Pfizer and its employees or agents for purposes relating to Pfizer's patient support programs, including, assisting the patient with benefits verification, prior authorization/appeals assistance, financial assistance resources and information, such as co-pay support or free drug programs, for which the patient may be eligible, and other support for Pfizer Oncology medication. I certify that I have obtained consent from the patient or the patient's caregiver to be contacted by Pfizer, Pfizer Oncology Together, and parties acting on their behalf using an autodialer or prerecorded voice at the telephone number(s) provided regarding the purposes described above and for other non-marketing purposes. I also give my permission to receive calls related to these services from Pfizer, Pfizer Oncology Together, and parties acting on their behalf, including calls made with an autodialer or prerecorded voice at the phone number(s) provided.							
HCP Signature*							Date*
HCP Email Address (Provide if signing ele	ectronically):						

TO BE COMPLETED BY HCP

Pfizer Oncology together[™]

HCPs fax the **completed** form to 1-877-736-6506 or mail to: Pfizer Oncology Together, PO Box 220366, Charlotte, NC 28222-0366. For questions, please call 1-877-744-5675, Monday–Friday, 8 AM–8 PM ET.

For details about how we collect and use personal information, including applicable U.S. state privacy rights and notices for California residents, please visit www.pfizer.com/privacy.

11. Patient Information *Required fields								
Patient Name (First/MI/Last)*	Patient Name (First/MI/Last)* Patient DOB (mm/dd/yyyy)*							
12. Diαgnosis				<u>. </u>				
Primary Diagnosis ICD-10*			Secondary I	Diagnosis ICD	-10			
Complete for Oral Medications								
13. Prescription Information for Orals 🕜 (Re	equired if prescribing	oral products.)						
Please check the medicine prescribed and inc	licate strength & q	uantity.* Please pro	ovide comple	te directions a	ınd dosing informat	ion below.		
□AROMASIN® (exemestane) 25 mg, 90-day su	AROMASIN® (exemestane) 25 mg, 90-day supply							
BOSULIF® (bosutinib) mg, 30-day								
□BRAFTOVI® (encorafenib) □300 mg, □450								
□ 30-day supply, l			_			ply, 🗖 Other:	— <u>-</u>	
□ DAURISMO™ (glasdegib sodium)r						mg, \square 28-day suppl	y □42-day supply	
☐ EMCYT® (estramustine phosphate sodium) 14		у			arib) m			
☐ IBRANCE® (palbociclib) mg, 28-da					itinib) m			
[†] Taken for 21 consecutive days followed by 7 days off treat	ment to comprise α con	nplete cycle of 28 days.	LIXALKO	RI® (crizotinib)) mg, 30	-day supply		
Directions/Dosing Instructions*:								
Concomitant Medications*:						Indicate number o	of refills*:	
Drug Allergies* ☐ Yes ☐ No (If yes, please list m	nedication[s] and asso	ociated reaction[s]):						
Other Known Conditions*:								
14. Prescription Signature								
Special Note: New York prescribers must e-prescri	be. To e-prescribe re	levant products, see	Pleαse Note υ	ınder Enrollme	nt Checklist for HCP	on page 4.		
I certify that I am the healthcare professional who has prescribed the therapy identified in this form. I further certify that I have made an independent judgment that the above therapy is medically necessary and that the information provided in this form is accurate to the best of my knowledge. I authorize Pfizer, and its affiliates, agents, representatives and service providers to act on my behalf for the purposes of transmitting this prescription to the appropriate pharmacy.								
				1 7				
HCP Signature* (Dispense As Written)		HCP Sign	nature* (Sub	stitution Allo	wed)		Date*	
HCP Email Address (Provide if signing electronically):								
15. Preferred Specialty Pharmacy (For comm	ercially insured pat	ients)						
Preferred Specialty Pharmacy Name*					☐ Self-D	Dispensing Pharmacy	у	
Preferred Specialty Pharmacy Address*								
The patient identified above prefers use of the Spec prescription to the Specialty Pharmacy designated then to a Specialty Pharmacy approved by this pati	above, provided it is	approved by this pati	ent's plan. If tl	ne Specialty Ph	armacy designated is	s not a plan-approved	Specialty Pharmacy,	
Complete for Injectable Medications								
16. Administering Provider Information (Administering/Overseeing Product Infusion)								
Name (First/MI/Last)* Specialty*								
NPI*	Group To	av ID*		State License*				
Practice Name*	Gloup II	ux 1D	Office Contact*					
Address*								
City*			State* ZIP Code*					
Phone* Fax* Email*								
17. Dosing Information for Injectables* 🕜 (Required if prescri	bing Provider-adm		•				
BESPONSA® (inotuzumab ozogamicin)	Vial Size	# of Vials			cin hydrochloride)	Vial Size	# of Vials	
CAMPTOSAR® (irinotecan hydrochloride)	Vial Size	# of Vials	Ozogan	ARG™ (gemtu: nicin)	zumab	Vial Size	# of Vials	
☐ ELLENCE® (epirubicin hydrochloride)	Vial Size	# of Vials \square TORISEL® (temsirolimus) Vial Size # of Via			# of Vials			
Treatment start date			Frequency of treatment*					

TO BE COMPLETED BY HCP

Pfizer Oncology together[™]

HCPs fax the **completed** form to 1-877-736-6506 or mail to: Pfizer Oncology Together, PO Box 220366, Charlotte, NC 28222-0366. For questions, please call 1-877-744-5675, Monday–Friday, 8 AM—8 PM ET.

For details about how we collect and use personal information, including applicable U.S. state privacy rights and notices for California residents, please visit www.pfizer.com/privacy.

Complete for Injectable Biosimilar Medicatio	ns							
18. Patient Information						*Required fields		
Patient Name (First/MI/Last)* Patient DOB (mm/dd/yyyy)*								
19. Diagnosis								
Primary Diagnosis ICD-10*			Secondary Diagnosis ICD-10					
The Prescribing Information for RUXIENCE™ does not include rheumatoid arthritis or pemphigus vulgaris. Support is not available for patients prescribed RUXIENCE™ to treat these conditions. □ Please check and sign here to confirm the patient does not have one of these conditions:								
The Prescribing Information for ZIRABEV™ does not include ovarian, fallopian tube, or peritoneal cancer. Support is not available for patients prescribed ZIRABEV™ to treat these conditions. □ Please check and sign here to confirm the patient does not have one of these conditions:								
20. Administering Provider Information (Administeri				ame a	s Section 7			
Name (First/MI/Last)*					Specialty*			
NPI* Group Tax	ID*		State Licen	se*		DEA		
Practice Name*			Office Cont	act*				
Address*								
City*					State*	ZIP Cod	e*	
Phone*	Fax*			Ema	il*			
21. Billing Address for Co-Pay Payment from the Pf on page 4 or Administering Provider Information above.)	izer Oncology Tog	ether Co-Pay	y Savings Pro	gram f	or Injectαbles (If differ	rent from th	e HCP/Site	of Care Information
Practice Billing Office Name*			Practice E	illing O	ffice Contact*			
Practice Billing Office Address*								
City*					State*	ZIP Cod	de*	
Practice Billing Phone*	Fax*			Emo	ail*			
22. Prescription Information for Injectables Biosimilars (Required if requesting assistance through Pfizer Patient Assistance Program.*)								
□NIVESTYM® (filgrastim-aafi) Single-Dose Vial			300 mcg/mL		480 mcg/1.6 mL			
□NIVESTYM® (filgrastim-aafi) Prefilled Syringe		300 mcg/0.5 mL			480 mcg/0.8 mL			
□ NYVEPRIA™ (pegfilgrastim-apgf) Prefilled Syringe			6 mg/0.6 mL					
□ RETACRIT® (epoetin alfa-epbx) Single-Dose Vial (1 mL)		2000 U/ml			3000 U/mL		4000 U/	mL
The Mental (epocent and epoxy single bose vial (1 me)		10,000 U/r			40,000 U/mL			
RETACRIT® (epoetin alfa-epbx) 1 x 10 Multi-Dose Vi *Doses for Pfizer Patient Assistance Program for RETACRIT® are only availab		20,000 U/1 mL			20,000 U/2 mL			
□RUXIENCE™ (rituximab-pvvr) Single-Dose Vial	_	100 mg/10 mL			500 mg/50 mL			
☐TRAZIMERA™ (trastuzumab-qyyp) Multi-Dose Vial		420 mg/vial						
□ZIRABEV™ (bevacizumab-bvzr) Single-Dose Vial		100 mg/4 mL			400 mg/16 mL			
Directions: Inject mcg of NIVESTYM®		Frequency:			Quantity:		Refills:	
Directions: Inject mcg of NYVEPRIA™		Frequency:			Quantity:		Refills:	
Directions: Inject units of RETACRIT®		Frequency:			Quantity:		Refills:	
Directions: Inject mg of RUXIENCE™		Frequency:			Quantity:		Refills:	
Directions: Inject mg of TRAZIMERA™		Frequency:			Quantity:		Refills:	
Directions: Inject mg of ZIRABEV™		Frequency: Quantity:			Quantity:		Refills:	
Drug Allergies* No Yes (If yes, please list medication[s] and associated reaction[s]):								
Concomitant Medications*:								
23. Prescription Signature (Required if requesting assistance through Pfizer Patient Assistance Program.†)								
Special Note: New York prescribers must e-prescribe. To e-prescribe relevant products, see Please Note under Enrollment Checklist for HCP on page 4.								
I certify that I am the healthcare professional who has prescribed the therapy identified in this form. I further certify that I have made an independent judgment that the above therapy is medically necessary and that the information provided in this form is accurate to the best of my knowledge. I authorize Pfizer, and its affiliates, agents, representatives and service providers to act on my behalf for the purposes of transmitting this prescription to the appropriate pharmacy.								
, ,			aprilate primitaej.					
HCP Signature* (Dispense As Written)		HCP Sigr	nature* (Subs	titutio	n Allowed)		_	Date*
HCP Email Address (Provide if signing electronically):								

Pfizer Oncology together™

HIPAA AUTHORIZATION FORM FOR THE DISCLOSURE OF PATIENT INFORMATION BY PERSONAL PHYSICIAN

To Physician

Please retain the original signed Authorization with the patient's records and provide a copy to the patient. You do not need to return this patient Authorization to Pfizer.

To Patient

By signing this form, I give my permission for my physicians, pharmacies, laboratories, and other healthcare providers ("Healthcare Providers") and my health insurers to share my health information with Pfizer Inc., the Pfizer Patient Assistance Foundation, Pfizer affiliates and its vendors (collectively, "Pfizer"). I understand that my health information includes information relating to my medical condition, treatment, and insurance coverage, as well as identifying information about me (including, for example, my name, address, and date of birth). My health information will be shared with Pfizer so that Pfizer may provide me with various support and information to help me access a Pfizer medicine, which may include the following, depending on your program (collectively, "Patient Support Activities"):

- Providing benefits investigations/verification and reimbursement support, including:
 - Assisting with identification of prior authorization requirements
 - Assisting with identification of requirements of your insurer for appeal of a denied claim
- Determining my eligibility for and helping me access co-pay support or free drug programs
- Sending me a device and starter kit (where appropriate)
- Communicating with my Healthcare Providers about a Pfizer medicine and Patient Support Activities
- Providing me with financial assistance resources and information if I'm eligible
- Providing me with disease management and other educational materials, as well as information about Pfizer's products, services, and programs, and may include sending me surveys about my experience with Pfizer products, services, and programs

Pfizer also may use my health information for quality assurance purposes and to evaluate and improve our operations and services.

I understand that I do not have to sign this form, and choosing not to sign will not affect my ability to receive treatment from my Healthcare Providers or payment from

my health insurer. However, if I do not sign this form, the Pfizer Oncology Together may not be able to provide me with assistance.

I understand that once my health information is shared, it may no longer be protected by federal privacy law. However, Pfizer agrees to protect my health information and to use it for the purposes described in this form or as required or permitted by law. Select pharmacies may receive remuneration from Pfizer in exchange for my health information and/or for any Patient Support Activities provided to me.

I understand that this form will remain in effect for 4 years from the date of my signature unless I provide written notice that I would like to withdraw my approval to share my health information sooner. If I would like to withdraw my approval, I may contact my physician or I may contact the Pfizer Oncology Together at P.O. Box 220366, Charlotte, NC 28222-0366 and call 1-877-744-5675, Monday—Friday, 8 AM—8 PM ET. This withdrawal will not affect the use or sharing of my health information that took place before I withdraw my approval. I understand I may receive a copy of this form.

I also give my permission to receive communications from Pfizer, the Pfizer Oncology Together, and parties acting on their behalf, including calls made with an autodialer or prerecorded voice at the phone number(s) provided to determine my eligibility and provide benefits verification, prior authorization/appeals assistance, and financial assistance resources and information, such as co-pay support or free drug programs, and for other non-marketing purposes. If I have a caregiver, he or she has also agreed to receive such communications from Pfizer, Pfizer Oncology Together, and/ or parties acting on their behalf for the purposes described above, and I hereby give my permission for Pfizer, Pfizer Oncology Together, and/or parties acting on their behalf to contact my caregiver for such purposes. I understand that I (and, if applicable, my caregiver) can opt-out of these communications at any time by contacting Pfizer Oncology Together at 1-877-744-5675, Monday–Friday, 8 AM-8 PM ET.

Patient Signature (Patient or personal representative of patient)					
If personal representative, indicate relationship.	Date				
Name (please print)					

